Company news

Atea Pharmaceuticals, Inc. news in 2025

Atea Pharmaceuticals, Inc.'s news releases, calls and decks from 2025, newest first.

View company

Atea Pharmaceuticals Completes Patient Enrollment in North American Phase 3 Trial Evaluating Regimen of Bemnifosbuvir and Ruzasvir for Treatment of Hepatitis C Virus

December 22, 2025

Atea Pharmaceuticals to Present at the 8th Annual Evercore Healthcare Conference

November 19, 2025

Atea Pharmaceuticals Reports Third Quarter 2025 Financial Results and Provides Business Update

November 12, 2025

Atea Pharmaceuticals Presents New Data Supporting the Fixed-Dose Combination of Bemnifosbuvir and Ruzasvir as a Potential Best-in-Class Regimen for Treatment of Hepatitis C Virus Infection at The Liver Meeting® 2025

November 7, 2025

Atea Pharmaceuticals to Host Third Quarter 2025 Financial Results and Business Update Conference Call on November 12, 2025

November 5, 2025

Atea Pharmaceuticals to Host Virtual HCV KOL Panel Event on November 13, 2025

October 22, 2025

Atea Pharmaceuticals to Present New Data Supporting Combination of Bemnifosbuvir and Ruzasvir as Potential Best-in-Class Regimen for Treatment of Hepatitis C Virus Infection at The Liver Meeting® 2025

October 7, 2025

Atea Pharmaceuticals to Present at the Morgan Stanley 23rd Annual Global Healthcare Conference

September 2, 2025

Atea Pharmaceuticals Reports Second Quarter 2025 Financial Results and Provides Business Update

August 7, 2025

Atea Pharmaceuticals to Host Second Quarter 2025 Financial Results and Business Update Conference Call on August 7, 2025

July 31, 2025

Atea Pharmaceuticals Announces Continued Advancement of Global Phase 3 HCV Program with Dosing of First Patient in C-FORWARD Outside North America

June 24, 2025

Atea Pharmaceuticals Reports First Quarter 2025 Financial Results and Provides Business Update

May 12, 2025

Atea Pharmaceuticals Announces Full Results from Phase 2 Study of Regimen of Bemnifosbuvir and Ruzasvir for Treatment of Hepatitis C Virus (HCV) Presented at EASL Congress 2025

May 7, 2025

Atea Pharmaceuticals to Host Virtual HCV KOL Panel on May 14, 2025

May 1, 2025

Atea Pharmaceuticals to Present New Data Showcasing Potential Best-in-Class Regimen of Bemnifosbuvir and Ruzasvir for Treatment of Hepatitis C Virus at EASL Congress 2025

April 23, 2025

Atea Pharmaceuticals Appoints Howard H. Berman to Board of Directors and Announces Share Repurchase Program

April 17, 2025

Atea Pharmaceuticals Announces Dosing of First Patient in C-BEYOND, Phase 3 Study Evaluating Regimen of Bemnifosbuvir and Ruzasvir for Treatment of Hepatitis C Virus

April 9, 2025

Atea Pharmaceuticals Highlights Actions Underway to Enhance Shareholder Value

March 26, 2025

Atea Pharmaceuticals Issues Statement Regarding Director Nominations

March 21, 2025

Atea Pharmaceuticals Announces Presentation of Bemnifosbuvir Preclinical Data at the 38th International Conference on Antiviral Research (ICAR) 2025

March 19, 2025

Atea Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update

March 6, 2025

Atea Pharmaceuticals to Host Fourth Quarter and Full Year 2024 Financial Results Conference Call on March 6, 2025

February 27, 2025

Atea Pharmaceuticals Appoints Arthur S. Kirsch to Board of Directors

February 24, 2025

Calls in 2025

Decks in 2025